AriBio advances patent push ahead of AR1001 Phase 3 results
AI Summary- AriBio is accelerating patent efforts for its AR1001 Alzheimer’s treatment candidate.
- AR1001 is an oral drug candidate whose active ingredient is mirodenafil.
- Global Phase 3 clinical trial results are due for release, according to AriBio.